SIRNAOMICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.5 HKD | -8.20% |
|
-16.20% | -79.05% |
| May. 20 | Sirnaomics' Strategy Chief Steps Down | MT |
| May. 17 | Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer | CI |
| Sales 2024 * | 2M 15.62M | Sales 2025 * | 70M 547M | Capitalization | 83.34M 651M |
|---|---|---|---|---|---|
| Net income 2024 * | -124M -969M | Net income 2025 * | - | EV / Sales 2024 * | 41.7 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.19 x |
| P/E ratio 2024 * |
-0.68
x | P/E ratio 2025 * |
-
| Employees | 145 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -8.20% | ||
| 1 week | -16.20% | ||
| Current month | +9.01% | ||
| 1 month | +27.77% | ||
| 3 months | -62.69% | ||
| 6 months | -84.04% | ||
| Current year | -79.05% |
1 week
7.40
9.56
1 month
5.9510.32
Current year
5.6436.00
1 year
5.6459.00
3 years
5.64101.00
5 years
5.64101.00
10 years
5.64101.00
| Managers | Title | Age | Since |
|---|---|---|---|
Patrick Lu
CEO | Chief Executive Officer | 68 | 20-10-14 |
Wing Kei Yip
DFI | Director of Finance/CFO | 39 | 18-09-30 |
David Evans
CTO | Chief Tech/Sci/R&D Officer | 61 | 21-07-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Mao Hua
BRD | Director/Board Member | 56 | 21-11-30 |
Patrick Lu
CEO | Chief Executive Officer | 68 | 20-10-14 |
David Evans
CTO | Chief Tech/Sci/R&D Officer | 61 | 21-07-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.50% | 4 M€ | -27.92% | ||
| 0.00% | 34 M€ | +4.20% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 7.5 | -8.20% | 4,103,500 |
| 24-05-23 | 8.17 | +0.49% | 3,677,300 |
| 24-05-22 | 8.13 | -2.05% | 5,670,200 |
| 24-05-21 | 8.3 | -9.49% | 4,115,750 |
| 24-05-20 | 9.17 | +2.46% | 6,584,050 |
Delayed Quote Hong Kong S.E., May 24, 2024 at 04:08 am EDT
More quotes
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.96
USD
Average target price
9.231
USD
Spread / Average Target
+861.60%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -79.05% | 83.34M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- 2257 Stock
